|1.||Duan, Yourong: 8 articles (12/2015 - 01/2012)|
|2.||Sun, Ying: 8 articles (12/2015 - 06/2012)|
|3.||Men, Ke: 8 articles (01/2015 - 09/2009)|
|4.||Chen, Xuesi: 7 articles (01/2016 - 03/2013)|
|5.||Wei, Yuquan: 7 articles (11/2015 - 06/2011)|
|6.||Lu, Weiyue: 7 articles (07/2015 - 05/2009)|
|7.||Qian, ZhiYong: 7 articles (01/2015 - 09/2009)|
|8.||Gao, Xiang: 7 articles (01/2015 - 01/2012)|
|9.||Liu, Peifeng: 7 articles (01/2014 - 01/2012)|
|10.||Tang, Zhaohui: 6 articles (01/2016 - 03/2013)|
12/01/2014 - "Anti-mPEG BsAbs offer a simple one-step method to confer tumor specificity to mPEG-NPs for enhanced tumor accumulation and improved therapeutic efficacy. "
12/01/2014 - "One-step mixing with humanized anti-mPEG bispecific antibody enhances tumor accumulation and therapeutic efficacy of mPEGylated nanoparticles."
06/15/2010 - "In conclusion, our data show that intratumoral injection of Ptx-loaded MPEG-PCL diblock copolymer yielded an in situ-forming gel that exhibited controlled Ptx release profile, and that was effective in treating localized solid tumors."
03/13/2013 - "The results demonstrated that mPEG-b-PLG was a promising vector to deliver DOX·HCl into tumors and achieve improved pharmacokinetics, biodistribution and efficacy of DOX·HCl with reduced toxicity. "
08/22/2014 - "In vivo, mPEG-NPOD-I reduced the size of the tumors significantly, and the biodistribution studies indicated that this drug conjugate could selectively accumulate in tumor tissues. "
|2.||Lung Neoplasms (Lung Cancer)
03/10/2013 - "PTX-mPEG-PCHLG-Nps achieved the highest antitumor activity in A549 rather than HepG-2, MCF-7 and C26, thus PTX-mPEG-PCHLG-Nps could have a potential application in lung cancer therapy. "
03/13/2013 - "Moreover, mPEG-b-PLG-DOX·HCl exhibited enhanced therapeutic efficacy, increased apoptosis in tumor tissues, and reduced systemic toxicity in nude mice bearing A549 lung cancer xenograft compared with free DOX·HCl, which were further confirmed by histological and immunohistochemical analyses. "
01/01/2013 - "We found advantages using Cur-Dox/MPEG-PCL micelles in the treatment of cancer, with Cur-Dox/MPEG-PCL achieving better inhibition of LL/2 lung cancer growth in vivo and in vitro. "
01/01/2013 - "The mechanism by which Cur-Dox/MPEG-PCL micelles inhibit lung cancer might involve increased apoptosis of tumor cells and inhibition of tumor angiogenesis. "
07/01/2015 - "In the present study, MPEG-PCL-TPGS was used as a novel nanovehicle for the delivery of paclitaxel (PTX) in the treatment of resistant lung cancers. "
|3.||Glioblastoma (Glioblastoma Multiforme)
08/01/2011 - "The biodistribution of RGD-PEG-PEI/pEGFP-N2 complexes in mice bearing subcutaneous glioblastomas were significantly greater than that of RGD-PEI-mPEG/pEGFP-N2 complexes, suggesting a more efficient gene transfection in vivo. "
12/15/2010 - "Furthermore, in vivo anti-glioblastoma effect exhibited the mean survive time of MPEG-NP/PTX (28 days) was much longer than those of Taxol injection (20 days) and NP/PTX (23 days). "
08/01/2013 - "In comparison with mPEG-PEI/pDNA for gene delivery, the RGD-PEG-SS-PEI/pDNA complex provided improved levels of transfection efficiency and reduced cytotoxicity when tested in U87 cells in vitro, and also enhanced levels of gene expression in the brains of intracranial U87 glioblastoma-bearing mice as demonstrated using dsRed gene transfer and bioimaging in vivo. "
08/01/2011 - "In this study, RGD-PEG-PEI and RGD-PEI-mPEG were synthesized and compared with respects to their glioblastoma cell-binding capability and tumor-targeting ability of their complexes with plasmid DNA. "
12/15/2010 - "More importantly, in vivo real-time fluorescence imaging analysis in intracranial C6 glioblastoma bearing mice showed that the methoxy poly(ethylene glycol)-poly(ɛ-caprolactone) nanoparticles (MPEG-NP) displayed much stronger fluorescence signal and 3-fold larger Area-Under-Curve (AUC) than poly(ɛ-caprolactone) conventional nanoparticles (NP) in tumor-bearing brain. "
|4.||Body Weight (Weight, Body)
08/01/2013 - "Despite this therapeutic profile, once daily injection of (pGlu-Gln)-CCK-8[mPEG] in high fat fed mice for 33days, at the same dose, was not associated with alterations in food intake and body weight. "
02/01/2009 - "Daily administration of GIP[mPEG] for 20 days had no effect on body weight and food intake. "
01/01/1995 - "No THOPP-MPEG phototoxicity in normal surrounding tissue at a dose of up to 100 mg/kg body weight was seen. "
08/01/2013 - "Sub-chronic twice daily injection of (pGlu-Gln)-CCK-8[mPEG] in high fat fed mice for 35days significantly decreased body weight gain (p<0.05), food intake (p<0.01 to p<0.001) and triacylglycerol deposition in liver (p<0.001) and muscle (p<0.001). "
01/01/1995 - "THOPP-MPEG was injected intraperitoneally (0.5 micrograms/g body weight) into the mice 6-8 days after tumor transplantation. "
07/07/2014 - "These results suggest that MTX-mPEG-CS NPs could be a promising targeting anticancer chemotherapeutic agent, especially for cervical carcinoma. "
06/01/2012 - "MTT assays used to study the in vitro cytotoxicity of mPEG-PLGA-b-PLL NPs showed that these particles were not toxic in huh-7 hepatic carcinoma cells. "
01/01/2015 - "Intriguingly, by treating with SH-ASA/Cur-coloaded mPEG-PLGA nanoparticles, obvious synergistic anticancer effects on ES-2 and SKOV3 human ovarian carcinoma cells were observed in vitro, and activation of the mitochondrial apoptosis pathway was indicated. "
05/01/2013 - "F-targeted lipoplexes could transfer gene into human ovarian carcinoma cell line SKOV-3, and 0.1% F-PEG-CLPs composed by DOTAP/Chol/mPEG-Chol/F-PEG-suc-Chol (50:45:5:0.1, molar ratio) had the highest transfection efficiency. "
09/28/2012 - "The biodegradable MPEG-PCL micelles entrapping PTX may have promising applications in pulmonary carcinoma therapy."
|3.||polylactic acid-polyglycolic acid copolymer (PLGA)
|8.||Polyethylene Glycols (Polyethylene Glycol)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)
|3.||Homologous Transplantation (Allograft)
|4.||Photochemotherapy (Photodynamic Therapy)